US regulators approved a new Merck  Co vaccine that is designed to offer broader protection than existing vaccines against cervical cancer and other cancers caused by a sexually transmitted virus Gardasil  which Merck codenamed V during development targets five additional strains of the human papillomavirus or HPV not targeted by the original Gardasil which Merck began selling in  The wider set of HPV types targeted by the new Gardasil vaccine is believed to account for nearly  of all cases of cervical
  